GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » EV-to-EBITDA

Moberg Pharma AB (Moberg Pharma AB) EV-to-EBITDA : -41.00 (As of May. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Moberg Pharma AB's enterprise value is $89.05 Mil. Moberg Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.17 Mil. Therefore, Moberg Pharma AB's EV-to-EBITDA for today is -41.00.

The historical rank and industry rank for Moberg Pharma AB's EV-to-EBITDA or its related term are showing as below:

MBGPF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -188.52   Med: 7.99   Max: 241.34
Current: -41.96

During the past 13 years, the highest EV-to-EBITDA of Moberg Pharma AB was 241.34. The lowest was -188.52. And the median was 7.99.

MBGPF's EV-to-EBITDA is ranked worse than
100% of 704 companies
in the Drug Manufacturers industry
Industry Median: 14.56 vs MBGPF: -41.96

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Moberg Pharma AB's stock price is $3.60. Moberg Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, Moberg Pharma AB's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Moberg Pharma AB EV-to-EBITDA Historical Data

The historical data trend for Moberg Pharma AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB EV-to-EBITDA Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 628.75 -7.85 -8.03 -6.48 -16.04

Moberg Pharma AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.48 -10.71 -2.30 -4.12 -16.04

Competitive Comparison of Moberg Pharma AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's EV-to-EBITDA falls into.



Moberg Pharma AB EV-to-EBITDA Calculation

Moberg Pharma AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=89.045/-2.172
=-41.00

Moberg Pharma AB's current Enterprise Value is $89.05 Mil.
Moberg Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (OTCPK:MBGPF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Moberg Pharma AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.60/0.000
=N/A

Moberg Pharma AB's share price for today is $3.60.
Moberg Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Moberg Pharma AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB (Moberg Pharma AB) Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.